comparemela.com

Page 7 - Mike Beyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting

Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses.

United statesJason lernerJennifer porcelliMike beyerPrnewswire biohaven ltdExchange commissionDeterminants of healthAmerican epilepsy society annual meetingBiohaven therapeutics ltdAmerican epilepsy societySam brown incBiohaven ltdEpilepsy societyAnnual meetingMedical directorEpilepsy clinical lead

Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies

TORONTO & WALTHAM, Mass. (BUSINESS WIRE) Nov 30, 2023

United statesMike beyerGirish aakaluAmanda thillPhenomic companyAstellas pharma incXyphos biosciences incPhenomic ai incSam brown incXyphos biosciencesBusiness wire

Phenomic Enters Strategic Collaboration with Boehringer Ingelheim to Discover Novel Targets for Stroma-Rich Cancer Therapies

TORONTO & WALTHAM, Mass. (BUSINESS WIRE) Nov 29, 2023

United statesGirish aakaluTheresa goletzAmanda thillMike beyerSam brown incAnimal healthBoehringer ingelheimPhenomic company contactImmune modulationHuman pharmaMedia contactBusiness wire

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Nov. 17, 2023 Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced.

United statesUniversity of pennsylvaniaStuart hendersonMike beyerHealthcare communicationsSam brown incUniversity of pennsylvania gene therapy programPassage bio incNasdaq listing rulePassage bioInducement optionsGene therapy programBio investorsBio media

Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment .

University of pennsylvaniaUnited statesMike beyerStuart hendersonWilliam chouExchange commissionPassage bio incUniversity of pennsylvania gene therapy programDevelopment rd expensesHealthcare communicationsSam brown incGene therapy programPrivate securities litigation reform actRisk factorsMonths ended september

vimarsana © 2020. All Rights Reserved.